New York, NY (PRWEB) May 16, 2007
Chimeracom L.L.C. (www.chimeracom.net) announced today that the US Patent and Trademark Office issued a US patent for the invention by Chimeracom’s Chief Science Officer, Dr. Richard M. Kream, of a novel method for managing a critical problem in the design of pharmaceuticals. As Dr. Kream explained, “the blood-brain barrier protects the brain from chemicals in the blood. This barrier must be overcome to deliver potentially important therapeutic and diagnostic agents to the brain. Our patent covers a family of new drugs for the delivery of pharmacologically active peptides into the brain.” This patent emerged from Chimeracom’s research and development of analgesic drugs.
The new US Patent is no. 7,214,657, entitled Method of Transporting a Chimeric Hybrid Molecule Across the Blood Brain Barrier.
About Chimeracom
Chimeracom is a privately-held company engaged in the research and development of novel analgesic drugs, which will alleviate pain without the adverse side effects of current analgesics, as well as compounds for treating drug abuse. URL:
http://www.chimeracom.net
DISCLOSURE NOTICE: The information contained in this release is as of May 14, 2007. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments. This release contains forward-looking information about the invention that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the licensing of the invention and/or design of drugs incorporating the patented method, completion of preclinical testing, the obtaining of investigational new drug approval and conduct and completion of clinical testing, the obtaining of new drug application approval, and the speed with which a product launch may be achieved, including the potential for difficulties or delays in manufacturing and marketing.
# # #
Find More Drug Abuse Press Releases